BioSpace News Archive

Atriva Therapeutics GmbH, a biopharmaceutical company that is pioneering the development of host-targeting antiviral therapies, announced today the topline findings from the Proof on Concept (POC) / Phase 2a RESPIRE study (zapnometinib) in patients hospitalized with moderate-to-severe COVID-19.

Amare Global, The Mental Wellness Company, announced today the acquisition of Kyäni, Inc., a globally recognized and respected pioneer in health and wellness with business operations in over 50 countries.

HAVN Life Sciences Inc. announces that the board of directors of the Company, on the advice of the Company’s Chief Financial Officer, has determined that the Company is no longer a going concern as it is unable to meet its financial obligations as they come due.

CEVEC Pharmaceuticals GmbH (CEVEC) and ROKOTE Laboratories Finland Ltd today announced the signing of an agreement on the use of CEVEC’s proprietary CAP® Ad Technology for the manufacturing of vaccines in various indications.

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray announced the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Application No. 16/469,092 for GIMOTI.

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced positive clinical data at the Transcatheter Cardiovascular Therapeutics Conference (“TCT”) held September 16-19 in Boston.

Lykan Bioscience, an innovative contract development and manufacturing organization focused on cell-based therapies, welcomes Barbara Ressler, Ph.D. as Vice President, Manufacturing Process Sciences.

Artiva Biotherapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug (IND) application for AB-201.

Immunis Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, has formally signed a clinical trial agreement with California Institute of Regenerative Medicine (CIRM) Alpha Stem Cell Clinics Network to initiate STEM-MYO Phase 1/2a clinical trials.

Updated 12-month results from the open-label investigator-initated Phase II clinical trial GADinLADA that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd® in individuals diagnosed with Latent Autoimmune Diabetes in Adults (LADA) were presented today at the European Association for the Study of Diabetes (EASD) conference in Stockholm, Sweden.